Targeted Degradation of CDK2: A New Strategy for Overcoming Cyclin E‑Driven Cancers.

Authors

Anna C Renner, Robert B Kargbo

Published in

ACS medicinal chemistry letters. Volume 17. Issue 8. Pages 1714-1717. Aug 13, 2026. Epub Jul 12, 2026.

Abstract

Cyclin-dependent kinase 2 (CDK2) has emerged as a critical oncogenic driver in cancers characterized by cyclin E amplification and resistance to existing cell-cycle therapies. A recent patent disclosure describes heterobifunctional degraders that selectively induce CDK degradation by recruiting E3 ligases. By eliminating rather than inhibiting CDK2, these compounds offer a promising approach to suppress tumor proliferation and overcome therapeutic resistance in cyclin E-dependent malignancies.

PMID:
42622017
Bibliographic data and abstract were imported from PubMed on 20 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.